Igm Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q: IGM Biosciences Reports Q2 2025 Results Amidst Sanofi Deal Termination and Concentra Merger Plans
IGM Biosciences announced a significant net income for Q2 2025 driven by the termination of its Sanofi collaboration agreement, while confirming a pending merger with Concentra Biosciences and substantial operational wind-down.
10-Q: IGM Biosciences Reports Q1 2025 Results, Announces Strategic Shift and Sanofi Agreement Termination
IGM Biosciences announces Q1 2025 financial results, a strategic shift involving halted development programs and workforce reductions, and the termination of its collaboration agreement with Sanofi.
IGM Biosciences reports a strategic shift to focus on autoimmunity, accompanied by a workforce reduction and pipeline reprioritization in its latest quarterly filing.
IGM Biosciences' second quarter 2024 results show a net loss of $47.9 million, with a strategic refocusing on immunology targets and the termination of oncology collaborations with Sanofi.
IGM Biosciences announced its first quarter 2024 financial results, highlighting a strategic shift to focus exclusively on immunology targets in its collaboration with Sanofi.